Roberto Bolli

Detailed analysis of bone marrow from patients with ischemic heart disease and left ventricular dysfunction: BM CD34, CD11b, and clonogenic capacity as biomarkers for clinical outcomes.

Nitric oxide donors induce late preconditioning against myocardial stunning and infarction in conscious rabbits via an antioxidant-sensitive mechanism.

Demonstration of an early and a late phase of ischemic preconditioning in mice.

The late phase of ischemic preconditioning is abrogated by targeted disruption of the inducible NO synthase gene.

Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits.

Evidence for an essential role of cyclooxygenase-2 as a mediator of the late phase of ischemic preconditioning in mice.

Gene therapy with extracellular superoxide dismutase protects conscious rabbits against myocardial infarction.

An essential role of the JAK-STAT pathway in ischemic preconditioning.

Opposing cardioprotective actions and parallel hypertrophic effects of delta PKC and epsilon PKC.

Oxidant species trigger late preconditioning against myocardial stunning in conscious rabbits.

Nitric oxide (NO) induces nitration of protein kinase Cepsilon (PKCepsilon ), facilitating PKCepsilon translocation via enhanced PKCepsilon -RACK2 interactions: a novel mechanism of no-triggered activation of PKCepsilon.

Formation of protein kinase C(epsilon)-Lck signaling modules confers cardioprotection.

Mitochondrial PKCepsilon and MAPK form signaling modules in the murine heart: enhanced mitochondrial PKCepsilon-MAPK interactions and differential MAPK activation in PKCepsilon-induced cardioprotection.

Inducible nitric oxide synthase modulates cyclooxygenase-2 activity in the heart of conscious rabbits during the late phase of ischemic preconditioning.

Role of nitric oxide in myocardial preconditioning.

Role of cyclic guanosine monophosphate in late preconditioning in conscious rabbits.

Role of Src protein tyrosine kinases in late preconditioning against myocardial infarction.

Gene dosage-dependent effects of cardiac-specific overexpression of the A3 adenosine receptor.

Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning.

Aldose reductase is an obligatory mediator of the late phase of ischemic preconditioning.

Delta-opioid receptor-induced late preconditioning is mediated by cyclooxygenase-2 in conscious rabbits.

Endoplasmic reticulum stress-dependent activation of ATF3 mediates the late phase of ischemic preconditioning.

Protein tyrosine kinase signaling is necessary for NO donor-induced late preconditioning against myocardial stunning.

Role of the JAK-STAT pathway in protection against myocardial ischemia/reperfusion injury.

MCC-134, a single pharmacophore, opens surface ATP-sensitive potassium channels, blocks mitochondrial ATP-sensitive potassium channels, and suppresses preconditioning.

Protein kinase Cepsilon interacts with and inhibits the permeability transition pore in cardiac mitochondria.

Use of fractional flow reserve versus stress perfusion scintigraphy after unstable angina. Effect on duration of hospitalization, cost, procedural characteristics, and clinical outcome.

Effect of aspirin on late preconditioning against myocardial stunning in conscious rabbits.

The role of sodium-hydrogen ion exchange in patients undergoing coronary artery bypass grafting.

Gene therapy with inducible nitric oxide synthase protects against myocardial infarction via a cyclooxygenase-2-dependent mechanism.

Mechanism of cyclooxygenase-2 upregulation in late preconditioning.

Nonelectrocardiographic evidence that both ischemic preconditioning and adenosine preconditioning exist in humans.

Nicorandil induces late preconditioning against myocardial infarction in conscious rabbits.

Administration of a CO-releasing molecule at the time of reperfusion reduces infarct size in vivo.

Cardioprotection during the final stage of the late phase of ischemic preconditioning is mediated by neuronal NO synthase in concert with cyclooxygenase-2.

Tumor necrosis factor-alpha does not modulate ischemia/reperfusion injury in naïve myocardium but is essential for the development of late preconditioning.

IL-6 plays an obligatory role in late preconditioning via JAK-STAT signaling and upregulation of iNOS and COX-2.

Hypercholesterolemia blunts NO donor-induced late preconditioning against myocardial infarction in conscious rabbits.

Delayed adaptation of the heart to stress: late preconditioning.

Overexpression of mitogen-activated protein kinase kinase 6 in the heart improves functional recovery from ischemia in vitro and protects against myocardial infarction in vivo.

Cells expressing early cardiac markers reside in the bone marrow and are mobilized into the peripheral blood after myocardial infarction.

Administration of a CO-releasing molecule induces late preconditioning against myocardial infarction.

Cardiac stem cells delivered intravascularly traverse the vessel barrier, regenerate infarcted myocardium, and improve cardiac function.

Delayed preconditioning-mimetic actions of nitroglycerin in patients undergoing exercise tolerance tests.

Myocardial regeneration by activation of multipotent cardiac stem cells in ischemic heart failure.

Late preconditioning induced by NO donors, adenosine A1 receptor agonists, and delta1-opioid receptor agonists is mediated by iNOS.

Cardiac preconditioning during percutaneous coronary interventions.

Gene therapy with iNOS provides long-term protection against myocardial infarction without adverse functional consequences.

Role of the protein kinase C-epsilon-Raf-1-MEK-1/2-p44/42 MAPK signaling cascade in the activation of signal transducers and activators of transcription 1 and 3 and induction of cyclooxygenase-2 after ischemic preconditioning.

Hypercholesterolemia abrogates late preconditioning via a tetrahydrobiopterin-dependent mechanism in conscious rabbits.

Adult bone marrow-derived cells: regenerative potential, plasticity, and tissue commitment.

The ubiquitous role of nitric oxide in cardioprotection.

Cardiac progenitor cells: the revolution continues.

No pain, no gain: the useful function of angina.

Postinfarct cytokine therapy regenerates cardiac tissue and improves left ventricular function.

Stem cell niches in the adult mouse heart.

Cardioprotection by postconditioning in conscious rats is limited to coronary occlusions <45 min.

Sca-1 expression is associated with decreased cardiomyogenic differentiation potential of skeletal muscle-derived adult primitive cells.

Preconditioning: a paradigm shift in the biology of myocardial ischemia.

Effects of anesthesia on echocardiographic assessment of left ventricular structure and function in rats.

Bone marrow for cardiac repair: the importance of characterizing the phenotype and function of injected cells.

Pretreatment with intracoronary enalaprilat protects human myocardium during percutaneous coronary angioplasty.

The late phase of ischemic preconditioning induces a prosurvival genetic program that results in marked attenuation of apoptosis.

Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis.

The late phase of preconditioning and its natural clinical application--gene therapy.

Endothelial nitric oxide synthase plays an obligatory role in the late phase of ischemic preconditioning by activating the protein kinase C epsilon p44/42 mitogen-activated protein kinase pSer-signal transducers and activators of transcription1/3 pathway.

Stromal cell derived factor-1 alpha confers protection against myocardial ischemia/reperfusion injury: role of the cardiac stromal cell derived factor-1 alpha CXCR4 axis.

The cardioprotection of the late phase of ischemic preconditioning is enhanced by postconditioning via a COX-2-mediated mechanism in conscious rats.

Human cardiac stem cells.

Cardioprotection afforded by inducible nitric oxide synthase gene therapy is mediated by cyclooxygenase-2 via a nuclear factor-kappaB dependent pathway.

CRYAB and HSPB2 deficiency alters cardiac metabolism and paradoxically confers protection against myocardial ischemia in aging mice.

Bone marrow cells adopt the cardiomyogenic fate in vivo.

Actions speak much louder than words: for midcareer and senior investigators, the track record of productivity should be paramount in selecting grant recipients.

Formation of large coronary arteries by cardiac progenitor cells.

Endothelial nitric oxide synthase is not necessary for the early phase of ischemic preconditioning in the mouse.

Loss of ischaemic preconditioning in ovariectomized rat hearts: possible involvement of impaired protein kinase C epsilon phosphorylation.

Transplantation of bone marrow-derived very small embryonic-like stem cells attenuates left ventricular dysfunction and remodeling after myocardial infarction.

Noncanonical Wnt11 signaling is sufficient to induce cardiomyogenic differentiation in unfractionated bone marrow mononuclear cells.

Bone marrow-derived pluripotent very small embryonic-like stem cells (VSELs) are mobilized after acute myocardial infarction.

Fms-related tyrosine kinase 3 expression discriminates hematopoietic stem cells subpopulations with differing engraftment-potential: identifying the most potent combination.

TGF-beta1 enhances cardiomyogenic differentiation of skeletal muscle-derived adult primitive cells.

Local activation or implantation of cardiac progenitor cells rescues scarred infarcted myocardium improving cardiac function.

Granulocyte colony-stimulating factor therapy for cardiac repair after acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials.

The role of TNF-alpha receptors p55 and p75 in acute myocardial ischemia/reperfusion injury and late preconditioning.

Notch1 regulates the fate of cardiac progenitor cells.

Impact of 6-mo caloric restriction on myocardial ischemic tolerance: possible involvement of nitric oxide-dependent increase in nuclear Sirt1.

Cardiac myocyte-specific expression of inducible nitric oxide synthase protects against ischemia/reperfusion injury by preventing mitochondrial permeability transition.

The cornucopia of "pleiotropic" actions of statins: myogenesis as a new mechanism for statin-induced benefits?

The beneficial effects of postinfarct cytokine combination therapy are sustained during long-term follow-up.

Gene transfer of inducible nitric oxide synthase affords cardioprotection by upregulating heme oxygenase-1 via a nuclear factor-{kappa}B-dependent pathway.

Intracoronary administration of cardiac progenitor cells alleviates left ventricular dysfunction in rats with a 30-day-old infarction.

Cardiac progenitor cells and bone marrow-derived very small embryonic-like stem cells for cardiac repair after myocardial infarction.

Hepatocyte growth factor/Met gene transfer in cardiac stem cells--potential for cardiac repair.

Cardioprotective and antiapoptotic effects of heme oxygenase-1 in the failing heart.

Circulation Research and human genetic studies.

Transplantation of expanded bone marrow-derived very small embryonic-like stem cells (VSEL-SCs) improves left ventricular function and remodelling after myocardial infarction.

Chronic AMD3100 antagonism of SDF-1alpha-CXCR4 exacerbates cardiac dysfunction and remodeling after myocardial infarction.

A murine model of inducible, cardiac-specific deletion of STAT3: its use to determine the role of STAT3 in the upregulation of cardioprotective proteins by ischemic preconditioning.

Intracoronary administration of cardiac stem cells in mice: a new, improved technique for cell therapy in murine models.

Hematopoietic cytokines for cardiac repair: mobilization of bone marrow cells and beyond.

Gene transfer as a strategy to achieve permanent cardioprotection I: rAAV-mediated gene therapy with inducible nitric oxide synthase limits infarct size 1 year later without adverse functional consequences.

Gene transfer as a strategy to achieve permanent cardioprotection II: rAAV-mediated gene therapy with heme oxygenase-1 limits infarct size 1 year later without adverse functional consequences.

New horizons in cardioprotection: recommendations from the 2010 National Heart, Lung, and Blood Institute Workshop.

Atorvastatin therapy during the peri-infarct period attenuates left ventricular dysfunction and remodeling after myocardial infarction.

Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial.

Carbon monoxide induces a late preconditioning-mimetic cardioprotective and antiapoptotic milieu in the myocardium.

Human cardiac stem cells isolated from atrial appendages stably express c-kit.

Identification of inducible nitric oxide synthase in peripheral blood cells as a mediator of myocardial ischemia/reperfusion injury.

The COX-2/PGI2 receptor axis plays an obligatory role in mediating the cardioprotection conferred by the late phase of ischemic preconditioning.

Cardiac stem cells in patients with ischemic cardiomyopathy: discovery, translation, and clinical investigation.

Genetic background, gender, age, body temperature, and arterial blood pH have a major impact on myocardial infarct size in the mouse and need to be carefully measured and/or taken into account: results of a comprehensive analysis of determinants of infarct size in 1,074 mice.

The heme oxygenase 1 inducer (CoPP) protects human cardiac stem cells against apoptosis through activation of the extracellular signal-regulated kinase (ERK)/NRF2 signaling pathway and cytokine release.

Administration of cardiac stem cells in patients with ischemic cardiomyopathy: the SCIPIO trial: surgical aspects and interim analysis of myocardial function and viability by magnetic resonance.

Cardiomyocyte-restricted overexpression of extracellular superoxide dismutase increases nitric oxide bioavailability and reduces infarct size after ischemia/reperfusion.

Protein O-GlcNAcylation is a novel cytoprotective signal in cardiac stem cells.

Stem cell therapy: promising treatment in heart failure?

A highly sensitive and accurate method to quantify absolute numbers of c-kit+ cardiac stem cells following transplantation in mice.

Phase II clinical research design in cardiology: learning the right lessons too well: observations and recommendations from the Cardiovascular Cell Therapy Research Network (CCTRN).

Intracoronary delivery of autologous cardiac stem cells improves cardiac function in a porcine model of chronic ischemic cardiomyopathy.

Vascular endothelial growth factor in heart failure.

The impact factor of circulation research rises 25%.

Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions.

Circulation Research launches a clinical track for studies in humans.

Reaching out to young investigators.

c-kit+ Cardiac stem cells alleviate post-myocardial infarction left ventricular dysfunction despite poor engraftment and negligible retention in the recipient heart.

Bone marrow mononuclear cell therapy for acute myocardial infarction: a perspective from the cardiovascular cell therapy research network.

Co-activation of nuclear factor-κB and myocardin/serum response factor conveys the hypertrophy signal of high insulin levels in cardiac myoblasts.

Cardiac stem cell therapy for cardiac repair.

Statistical Methods for Selecting Maximum Effective Dose and Evaluating Treatment Effect When Dose - Response is Monotonic.

Identification of heme oxygenase 1 (HO-1) as a novel negative regulator of mobilization of hematopoietic stem/progenitor cells.

Response to letter regarding article, "Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions".

The NHLBI-sponsored Consortium for preclinicAl assESsment of cARdioprotective therapies (CAESAR): a new paradigm for rigorous, accurate, and reproducible evaluation of putative infarct-sparing interventions in mice, rabbits, and pigs.

"String theory" of c-kit(pos) cardiac cells: a new paradigm regarding the nature of these cells that may reconcile apparently discrepant results.

Safety of intracoronary infusion of 20 million C-kit positive human cardiac stem cells in pigs.

Glutamine Regulates Cardiac Progenitor Cell Metabolism and Proliferation.

Effects of Intracoronary Infusion of Escalating Doses of Cardiac Stem Cells in Rats With Acute Myocardial Infarction.

Comparison of coliform contamination in non-municipal waters consumed by the Mennonite versus the non-Mennonite rural populations.

Effect of the stop-flow technique on cardiac retention of c-kit positive human cardiac stem cells after intracoronary infusion in a porcine model of chronic ischemic cardiomyopathy.

Genetic Deficiency of Glutathione S-Transferase P Increases Myocardial Sensitivity to Ischemia-Reperfusion Injury.

Preconditioning Human Cardiac Stem Cells with an HO-1 Inducer Exerts Beneficial Effects After Cell Transplantation in the Infarcted Murine Heart.

Current status of cell therapy for non-ischaemic cardiomyopathy: a brief overview.

C-Kit Promotes Growth and Migration of Human Cardiac Progenitor Cells via the PI3K-AKT and MEK-ERK Pathways.

Cell Therapy Needs Rigorous Translational Studies in Large Animal Models.

O-GlcNAcylation Negatively Regulates Cardiomyogenic Fate in Adult Mouse Cardiac Mesenchymal Stromal Cells.

Identification of Bone Marrow Cell Subpopulations Associated With Improved Functional Outcomes in Patients With Chronic Left Ventricular Dysfunction: An Embedded Cohort Evaluation of the FOCUS-CCTRN Trial.

Concise Review: Review and Perspective of Cell Dosage and Routes of Administration From Preclinical and Clinical Studies of Stem Cell Therapy for Heart Disease.

Long-Term Outcome of Administration of c-kit(POS) Cardiac Progenitor Cells After Acute Myocardial Infarction: Transplanted Cells Do not Become Cardiomyocytes, but Structural and Functional Improvement and Proliferation of Endogenous Cells Persist for at Least One Year.

Impact of Cell Therapy on Myocardial Perfusion and Cardiovascular Outcomes in Patients With Angina Refractory to Medical Therapy: A Systematic Review and Meta-Analysis.

Type 2 Diabetes Dysregulates Glucose Metabolism in Cardiac Progenitor Cells.

STAT3 Signaling in B Cells Is Critical for Germinal Center Maintenance and Contributes to the Pathogenesis of Murine Models of Lupus.

Repeated Administrations of Cardiac Progenitor Cells Are Markedly More Effective Than a Single Administration: A New Paradigm in Cell Therapy.

The Epigenetic Regulator HDAC1 Modulates Transcription of a Core Cardiogenic Program in Human Cardiac Mesenchymal Stromal Cells Through a p53-Dependent Mechanism.

A New Method to Stabilize C-Kit Expression in Reparative Cardiac Mesenchymal Cells.

TNF receptor signaling inhibits cardiomyogenic differentiation of cardiac stem cells and promotes a neuroadrenergic-like fate.

Bone marrow cell characteristics associated with patient profile and cardiac performance outcomes in the LateTIME-Cardiovascular Cell Therapy Research Network (CCTRN) trial.

Oxygen Administration Does Not Influence the Prognosis of Acute Myocardial Infarction: A Meta-Analysis.

Identification of cardiovascular risk factors associated with bone marrow cell subsets in patients with STEMI: a biorepository evaluation from the CCTRN TIME and LateTIME clinical trials.

Introducing Yet Another Addition to Our Portfolio: Promising Young Investigators.

Increased Risk of Adverse Neurocognitive Outcomes With Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors.

Repeated Cell Therapy: A Paradigm Shift Whose Time Has Come.

Evaluation of Cell Therapy on Exercise Performance and Limb Perfusion in Peripheral Artery Disease: The CCTRN PACE Trial (Patients With Intermittent Claudication Injected With ALDH Bright Cells).

Repeated doses of cardiac mesenchymal cells are therapeutically superior to a single dose in mice with old myocardial infarction.

Transcription factor-induced activation of cardiac gene expression in human c-kit+ cardiac progenitor cells.

Stem cells: Cell therapy for cardiac repair: what is needed to move forward?

Myocardial Reparative Properties of Cardiac Mesenchymal Cells Isolated on the Basis of Adherence.

Peripheral Blood Cytokine Levels After Acute Myocardial Infarction: IL-1β- and IL-6-Related Impairment of Bone Marrow Function.

Global position paper on cardiovascular regenerative medicine.

The Promise and Challenge of Induced Pluripotent Stem Cells for Cardiovascular Applications.

Circulating Biomarkers to Identify Responders in Cardiac Cell therapy.

Histone Deacetylase 1 Depletion Activates Human Cardiac Mesenchymal Stromal Cell Proangiogenic Paracrine Signaling Through a Mechanism Requiring Enhanced Basic Fibroblast Growth Factor Synthesis and Secretion.

Cardiomyocyte Regeneration: A Consensus Statement.

The Impact Factor of Reaches a New High.

Overcoming the Roadblocks to Cardiac Cell Therapy Using Tissue Engineering.

New Initiatives to Improve the Rigor and Reproducibility of Articles Published in .

Short and Long Noncoding RNAs Regulate the Epigenetic Status of Cells.

Cell therapy for heart disease: current status and future directions.

Global Overview of the Transnational Alliance for Regenerative Therapies in Cardiovascular Syndromes (TACTICS) Recommendations: A Comprehensive Series of Challenges and Priorities of Cardiovascular Regenerative Medicine.

Translational Research in Cardiovascular Repair: A Call for a Paradigm Shift.

Guidelines for experimental models of myocardial ischemia and infarction.

Repeated Administrations of Cardiac Progenitor Cells Are Superior to a Single Administration of an Equivalent Cumulative Dose.

Author Correction: Circulating Biomarkers to Identify Responders in Cardiac Cell therapy.

A Call to Make the Human Dimension of Science a Core Component of Scientific Journals.

Rationale and Design of the CONCERT-HF Trial (Combination of Mesenchymal and c-kit Cardiac Stem Cells As Regenerative Therapy for Heart Failure).

Rationale and Design of the SENECA (StEm cell iNjECtion in cAncer survivors) Trial.

Introduction to a Compendium on Regenerative Cardiology.

New Paradigms in Cell Therapy: Repeated Dosing, Intravenous Delivery, Immunomodulatory Actions, and New Cell Types.

Clinical Studies of Cell Therapy in Cardiovascular Medicine: Recent Developments and Future Directions.

Cardiac stem cells in patients with ischaemic cardiomyopathy - Authors' reply.

Effect of Molecular Weight on Sonoporation-Mediated Uptake in Human Cells.

Cardiac mesenchymal cells from diabetic mice are ineffective for cell therapy-mediated myocardial repair.

Introduction to Cardiovascular Aging Compendium.

The Impact Factor of Circulation Research Reaches Another New High.

Epigenetically modified cardiac mesenchymal stromal cells limit myocardial fibrosis and promote functional recovery in a model of chronic ischemic cardiomyopathy.

Convergences of Life Sciences and Engineering in Understanding and Treating Heart Failure.

TRPA1 channel contributes to myocardial ischemia-reperfusion injury.

Potential Strategies for Clinical Translation of Repeated Cell Therapy.

Perspectives on Directions and Priorities for Future Preclinical Studies in Regenerative Medicine.

William Harvey and the Discovery of the Circulation of the Blood.

Human Embryonic Stem Cell-Derived Cardiomyocytes.

William Harvey and the Discovery of the Circulation of the Blood.

Transcription Factor STAT3 Serves as a Negative Regulator Controlling IgE Class Switching in Mice.

William Harvey and the Discovery of the Circulation of the Blood.

Pro-Angiogenic Actions of CMC-Derived Extracellular Vesicles Rely on Selective Packaging of Angiopoietin 1 and 2, but Not FGF-2 and VEGF.

Ten Years at the Helm of Circulation Research.

Inducible cardiac-specific overexpression of cyclooxygenase-2 (COX-2) confers resistance to ischemia/reperfusion injury.

Physiological Biomimetic Culture System for Pig and Human Heart Slices.

A realistic appraisal of the use of embryonic stem cell-based therapies for cardiac repair.

Meta-analysis of short- and long-term efficacy of mononuclear cell transplantation in patients with myocardial infarction.

Time to end the war on cell therapy.